Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. (2023)

First Author: Attard G
Attributed to:  Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(23)00148-1

PubMed Identifier: 37142371

Publication URI: http://europepmc.org/abstract/MED/37142371

Type: Journal Article/Review

Volume: 24

Parent Publication: The Lancet. Oncology

Issue: 5

ISSN: 1470-2045